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Abstract: This study examined the utility of combination therapy for bloodstream isolates of
Enterobacteriaceae and non-fermenting Gram-negative bacilli (NFGN) from adults at two community
hospitals from January 2010 through to June 2015. Changes to in vitro antimicrobial susceptibilities
by adding ciprofloxacin or gentamicin to third-generation cephalosporins (3GC) were examined
overall and in patients with risk factors for 3GC resistance. Overall ceftriaxone susceptibility among
Enterobacteriaceae was 996/1063 (94%) and 247/295 (84%) in patients with 3GC resistance risk factors.
Susceptibilities increased marginally by adding ciprofloxacin or gentamicin (mean difference 2.4%
(95% CI 1.5, 3.4) and 3.0% (95% CI 2.0, 4.0), respectively, overall and 5.4% (95% CI 2.8, 8.0) and 7.1%
(95% CI 4.2, 10.1), respectively, in patients with risk factors). Eighty-three of 105 (79%) NFGN were
susceptible to ceftazidime overall and 20/29 (69%) in patients with prior beta-lactam use. Overall
mean increase in susceptibilities was 15.2% (95% CI: 8.3, 22.2) and 17.1% (95% CI: 9.8, 24.5) for
ciprofloxacin and gentamicin combinations, respectively; and 27.6% (95% CI: 10.3, 44.9) for either
one with recent beta-lactam use. In this setting, empirical combination therapy had limited utility for
Enterobacteriaceae bloodstream isolates but provided significant additional antimicrobial coverage to
ceftazidime for NFGN, particularly in patients with prior beta-lactam use.
Keywords: bacteremia; antibiotics; Escherichia coli; Klebsiella species; Pseudomonas aeruginosa; extended-spectrum
beta-lactamases; AmpC; sepsis
1. Introduction
Increasing antimicrobial resistance rates continue to challenge the approach to empirical
antimicrobial selection [1,2]. The use of two antimicrobial agents from different classes may increase the
appropriateness of empirical coverage [3]. However, the role of empirical combination antimicrobial
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therapy in Gram-negative bloodstream infections (BSI) remains uncertain. Earlier studies demonstrated
inconsistent conclusions [4–11]. The results of more recent studies suggest no benefit from the
nonstratified use of combination therapy in Gram-negative BSI [12–18]. However, antimicrobial
resistance rates of Gram-negative bacilli to broad-spectrum beta-lactams, such as third-generation
cephalosporins (3GC), remain high in the setting of prior beta-lactam use among other risk factors for
3GC resistance [19–21]. It is hypothesized that the addition of a fluoroquinolone or an aminoglycoside
to 3GC may increase the appropriateness of empirical antimicrobial regimens in these high-risk patients.
The use of combination therapy in these settings may be an alternative antimicrobial stewardship
strategy to the empirical use of carbapenems or new, more expensive beta-lactam/extended-spectrum
beta-lactamase (ESBL) inhibitors. This study examined the potential benefit of combination therapy
on the appropriateness of empirical antimicrobial regimens in adult patients with BSI due to
Enterobacteriaceae and non-fermenting Gram-negative bacilli (NFGN) overall and after stratification
based on risk factors for 3GC resistance at initial presentation.
2. Results
2.1. Clinical Characteristics and Microbiology
A total of 1168 patients with BSI were included in the study; 1063 (91%) due to Enterobacteriaceae
and 105 (9%) due to NFGN. Escherichia coli (597; 51%) was the most common bloodstream isolate
overall, followed by Klebsiella pneumoniae (225; 19%), Proteus mirabilis (78; 7%), Enterobacter spp. (76; 6%),
and other Enterobacteriaceae (87; 8%). Pseudomonas aeruginosa (70; 6%) was the most common among
NFGN, followed by Acinetobacter spp. (17; 1.5%) and other NFGN (18; 1.5%). Demographics and
clinical characteristics of patients with BSI due to Enterobacteriaceae and NFGN are shown in Table 1.
Table 1. Demographics and clinical characteristics of patients with bloodstream infections.
Variable Enterobacteriaceae (n =1063) NFGN (n = 105)
Age in y, median (IQR) 65 (54-77) 63 (51-75)
Female sex 575 (54) 45 (43)
Ethnicity
White 497 (47) 46 (44)
African American 529 (50) 54 (51)
Other 37 (3) 5 (5)
Diabetes mellitus 415 (39) 36 (34)
End-stage renal disease 106 (10) 14 (13)
Liver cirrhosis 51 (5) 4 (4)
Cancer 175 (16) 26 (25)
Immune compromised host 118 (8) 25 (24)
Indwelling central venous catheter 207 (19) 34 (32)
Indwelling urinary catheterization 123 (12) 14 (13)
Residence at skilled nursing facility 164 (15) 10 (10)
Recent hospitalization* 328 (31) 42 (40)
Hospital-acquired infection 228 (21) 38 (36)
Pitt bacteremia score ≥4 233 (22) 24 (23)
Data are shown as number (%) unless otherwise specified. NFGN: Non-fermenting Gram-negative bacilli; IQR:
Interquartile range. * Within 90 days of bloodstream infection.
2.2. Additional Antimicrobial Coverage of Combination Regimens
Among Enterobacteriaceae bloodstream isolates, 94% were susceptible to ceftriaxone with
a marginal change in susceptibilities by adding either ciprofloxacin or gentamicin (Table 2). In patients
with risk factors for 3GC resistance, 84% of Enterobacteriaceae bloodstream isolates were susceptible
to ceftriaxone. Adding ciprofloxacin or gentamicin to ceftriaxone improved susceptibilities of
combination regimen by only 5.4% and 7.1%, respectively.
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A substantial change in susceptibility was observed with the addition of either ciprofloxacin
or gentamicin to ceftazidime among NFGN (mean difference 15.2% and 17.1%, respectively).
Antimicrobial susceptibility of NFGN to ceftazidime was 69% in patients with prior use of beta-lactams
within the past 30 days. The addition of ciprofloxacin or gentamicin to ceftazidime increased
susceptibility rates to 97% for each respective combination regimen. Similar patterns were observed
among bloodstream isolates of P. aeruginosa, where ceftazidime susceptibility rates were 81% and
96% in the presence or absence of recent beta-lactam exposure, respectively. The addition of either
ciprofloxacin or gentamicin significantly improved the appropriateness of the empirical regimen only
in patients with prior beta-lactam use (Table 2).
Table 2. Antimicrobial susceptibility of bloodstream isolates in patients with and without risk factors
for third-generation cephalosporin resistance.
Bacteria 3GC n (%) 3GC/FQ n(%) MD (95% CI) p
3GC/AG n
(%) MD (95% CI) p
Enterobacteriaceae
Overall
(n = 1063) 996 (94) 1022 (96) 2.4 (1.5, 3.4) <0.001 1028 (97) 3.0 (2.0, 4.0) <0.001
No 3GC-R risk
factors* (n = 768) 750 (98) 760 (99) 1.3 (0.5, 2.1) 0.002 761 (99) 1.4 (0.6, 2.3) <0.001
3GC-R risk factors* (n
= 295) 247 (84) 263 (89) 5.4 (2.8, 8.0) <0.001 268 (91) 7.1 (4.2, 10.1) <0.001
Non-fermenting Gram-negative bacilli
Overall
(n = 105) 83 (79) 99 (94) 15.2 (8.3, 22.2) <0.001 101 (96) 17.1 (9.8, 24.5) <0.001
No recent use of
beta-lactams+
(n = 76)
63 (83) 71 (93) 10.5 (3.7, 17.6) 0.004 73 (96) 13.2 (5.4, 20.9) 0.001
Recent beta-lactam
use+
(n = 29)
20 (69) 28 (97) 27.6 (10.3, 44.9) 0.003 28 (97) 27.6 (10.3, 44.9) 0.003
Pseudomonas aeruginosa
Overall
(n = 70) 64 (91) 70 (100) 8.6 (1.8, 15.3) 0.01 70 (100) 8.6 (1.8, 15.3) 0.01
No recent use of
beta-lactams+
(n = 49)
47 (96) 49 (100) 4.1 (-1.7, 9.8) 0.16 49 (100) 4.1 (-1.7, 9.8) 0.16
Recent beta-lactam
use+
(n = 21)
17 (81) 21 (100) 19.0 (7.1, 37.4) 0.04 21 (100) 19.0 (7.1, 37.4) 0.04
3GC: Third-generation cephalosporin (ceftriaxone for Enterobacteriaceae and ceftazidime for non-fermenters); FQ:
Fluoroquinolone (ciprofloxacin); MD: Mean difference; CI: Confidence interval; AG: Aminoglycoside (gentamicin);
3GC-R: Third-generation cephalosporin resistance. * Risk factors for third-generation cephalosporin resistance
include prior beta-lactam or fluoroquinolone use within the past 3 months, prior infections or colonization
with extended-spectrum beta-lactamase producing Enterobacteriaceae within the past 12 months, and recent
outpatient gastrointestinal or genitourinary procedures within the past one month [20]. + Within 30 days of
bloodstream infection.
2.3. Correlation between Susceptibilities of Different Antimicrobial Classes
Overall, 83% and 93% of Enterobacteriaceae bloodstream isolates were susceptible to ciprofloxacin
and gentamicin, respectively. When stratified by susceptibility to ceftriaxone, only 39% and 48%
of ceftriaxone-nonsusceptible Enterobacteriaceae were susceptible to ciprofloxacin and gentamicin,
respectively (Table 3). Susceptibilities for these agents among ESBL-producing Enterobacteriaceae were
even lower (21% and 31%, respectively), limiting the utility of combination therapy when needed the
most. There was a positive correlation between antimicrobial susceptibilities of ceftriaxone and both
ciprofloxacin and gentamicin in Enterobacteriaceae bloodstream isolates (Table 4). This correlation was
mostly driven by bloodstream isolates of E. coli, Klebsiella spp., and Proteus mirabilis. There was a lack
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of correlation between susceptibilities to ceftriaxone and either combination agent among Enterobacter,
Serratia, and Citrobacter spp. bloodstream isolates.
Overall antimicrobial susceptibility rates to ciprofloxacin and gentamicin among NFGN were 85%
and 88%, respectively. Susceptibility to ciprofloxacin and gentamicin was retained among 73% and
82% of ceftazidime-nonsusceptible NFGN, respectively (Table 3). No correlation between antimicrobial
susceptibilities of ceftazidime and either ciprofloxacin or gentamicin was detected in NFGN (Table 4).
Table 3. Antimicrobial susceptibilities of bloodstream isolates to combination agent based on
susceptibility to third-generation cephalosporins.
Bacteria Ciprofloxacin p Gentamicin p
Enterobacteriaceae 880/1058 (83) 997/1053 (93)
Ceftriaxone-susceptible
Ceftriaxone-nonsusceptible
854/992 (86)
26/66 (39) <0.001
945/987 (96)
32/66 (48) <0.001
NFGN 88/104 (85) 92/105 (88)
Ceftazidime-susceptible
Ceftazidime-nonsusceptible
72/82 (88)
16/22 (73) 0.08
74/83 (89)
18/22 (82) 0.35
Data are shown as number of susceptible isolates/number of isolates tested (percentage of susceptible isolates).
NFGN: Non-fermenting Gram-negative bacilli.
Table 4. Correlation between in vitro antimicrobial susceptibilities of bloodstream isolates to
third-generation cephalosporins and combination agents.
Bacteria
Ciprofloxacin Gentamicin
κ (95% CI) p κ (95% CI) p
Enterobacteriaceae 0.27 (0.19, 0.34) <0.001 0.45 (0.35, 0.56) <0.001
E. coli, Klebsiella spp. and P. mirabilis 0.30 (0.22, 0.38) <0.001 0.52 (0.41, 0.63) <0.001
Enterobacter, Serratia and Citrobacter
spp. -0.07 (-0.10, 0.04) 0.38
-0.06 (-0.09,
0.03) 0.47
Non-fermenting Gram-negative bacilli 0.17 (-0.05, 0.38) 0.08 0.09 (-0.12, 0.29) 0.35
P. aeruginosa -0.10 (-0.16, 0.05) 0.39 -0.04 (-0.09,0.01) 0.66
Other non-fermenters 0.21 (-0.09, 0.51) 0.17 -0.12 (-0.43,0.19) 0.45
κ: Kappa coefficient; CI: confidence intervals.
3. Discussion
3.1. Clinical Applications of Study Findings
This study demonstrates that the empirical use of combination antimicrobial therapy has limited
utility in patients with BSI due to Enterobacteriaceae. Compared to monotherapy with ceftriaxone,
the addition of ciprofloxacin or gentamicin provided only marginal difference in the susceptibilities
of Enterobacteriaceae bloodstream isolates overall. Even in patients with specific risk factors for
antimicrobial resistance where susceptibility of Enterobacteriaceae bloodstream isolates to ceftriaxone
was only 84%, combination therapy with ciprofloxacin or gentamicin did not provide considerable
gains (89% and 91%, respectively). These susceptibility rates of combination regimens are unlikely
to meet healthcare providers’ expectations for empirical antimicrobial regimens in patients with
potentially life-threatening infections, such as BSI [22–24]. Moreover, considering the potential adverse
events from either ciprofloxacin or gentamicin and high numbers needed to treat to improve the
appropriateness of empirical therapy by adding either agent to ceftriaxone (19 and 14, based on mean
differences of 5.4% and 7.1%, respectively), it is likely the potential risks of combination therapy exceed
the benefits in this setting. The current results do not support the use of combination antimicrobial
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therapy as a carbapenem-sparing option in patients with risk factors for BSI due to ESBL-producing
Enterobacteriaceae in our local population or others with similar antimicrobial resistance patterns.
Conversely, in patients with BSI due to NFGN, including P. aeruginosa, combination therapy
significantly improved the appropriateness of the empirical regimen over ceftazidime monotherapy,
particularly in the setting of recent beta-lactam use. This emphasizes the concept of stratifying
patients based on prior antimicrobial use in order to improve the selection of empirical antimicrobial
therapy. Applying this stratified empirical approach, the use of combination therapy would have been
entertained in only 30% (21/70) of patients with P. aeruginosa BSI. Among this subset of patients
with P. aeruginosa BSI and prior beta-lactam exposure, the numbers needed to treat to improve
appropriateness of empirical therapy was only five (based on a mean difference of 19%), making
this a reasonable strategy in critically-ill patients. For the remaining patients without prior beta-lactam
use, ceftazidime monotherapy provided appropriate coverage for 96% of P. aeruginosa bloodstream
isolates, negating the need for a combination agent. The small number and heterogeneity of other
NFGN in this study make it difficult to draw meaningful conclusions regarding this group of bacteria.
Further studies to delineate the potential benefits of combination antimicrobial regimens in these
patients are warranted.
3.2. Potential Explanations for Correlation between Susceptibilities of Different Antimicrobial Classes
The discordant results regarding the utility of combination regimens in Enterobacteriaceae and
P. aeruginosa bloodstream isolates may be explained by the different resistance mechanisms present in
the respective bacteria. The study demonstrates a fair agreement between susceptibilities of ceftriaxone
and ciprofloxacin, and a moderate agreement between ceftriaxone and gentamicin susceptibilities
among Enterobacteriaceae bloodstream isolates (Table 4). This is conceivable given that phenotypic
screening test for ESBL production was positive in the majority of ceftriaxone-nonsusceptible
Enterobacteriaceae in this study (42/66; 64%). It is likely these isolates often carry resistance genes
to other antimicrobial classes such as fluoroquinolones or aminoglycosides on the same or other
plasmids [25]. Although P. aeruginosa can carry ESBL on plasmids, this remains relatively uncommon
compared to Enterobacteriaceae [25–27]. More common resistance mechanisms to ceftazidime among
P. aeruginosa isolates include chromosomally-mediated AmpC-production, efflux pumps, and outer
membrane protein alterations or mutations [26,27]. However, multidrug efflux pumps may contribute
to resistances to ceftazidime and other classes of antimicrobials in P. aeruginosa [28].
3.3. Impact of Antimicrobial Utilization in Hospitals on Choice of Combination Agent
It was noted in this study that fluoroquinolone and aminoglycoside combinations provided
comparable antimicrobial susceptibility results for NFGN, including P. aeruginosa. This is likely
explained by the overall low utilization of fluoroquinolones in the two hospitals included in this
study (mean of 30 days of therapy per 1000 patient-days during the study period). This has
contributed to overall low resistance rates to fluoroquinolones in NFGN, which are predominantly
hospital-onset bacteria. However, in institutions with relatively higher fluoroquinolone utilization
and fluoroquinolone resistance rates among P. aeruginosa and other NFGN, it is expected that
aminoglycoside combinations would be more beneficial than fluoroquinolone combination regimens.
Knowledge of local hospital epidemiology, antimicrobial utilization, and antimicrobial resistance rates
is essential to determine the potential benefits of either combination regimen in each institution.
3.4. Antimicrobial Stewardship Implications
The results of this study offer insights into the utility of combination antibiograms as tools for
informed antimicrobial prescribing in hospitals [29]. However, we caution antimicrobial stewardship
programs to selectively report combination antibiograms for bacteria only in settings where it would
be clinically useful in order to minimize misuse and misinterpretation. The results of the current study
argue that reporting a combination antibiogram in similar hospitals is only useful for P. aeruginosa and
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possibly other NFGN in the setting of recent beta-lactam use. It would also be useful for stewardship
teams to list risk factors for BSI due to P. aeruginosa, such as immune compromised hosts and prolonged
hospitalization in the footnotes of such combination antibiograms [30].
3.5. Strengths and Limitations
The study used a unique approach to identify patients with Gram-negative BSI who may benefit
from empirical combination antimicrobial therapy. It examined the utility of combination regimens
based on predicted risk of antimicrobial resistance at initial presentation, and then confirmed these
findings based on correlation between actual susceptibilities of bloodstream isolates to different
antimicrobial classes.
Limitations of this study include enrollment of patients with BSI from two hospitals from
a single healthcare system subject to local epidemiology, antimicrobial resistance, and specific
patient populations. The study results may not be generalizable to other institutions with
different hospital epidemiology and antimicrobial resistance patterns. The study did not examine
antimicrobial susceptibility rates of amikacin since it was not consistently performed in bloodstream
isolates throughout the study period. This may have underestimated the potential benefits from
aminoglycoside combinations in Enterobacteriaceae [31]. Moreover, the current investigation did not
examine susceptibilities to the more recent, novel beta-lactam/beta-lactamase inhibitors, such as
ceftolozane–tazobactam and ceftazidime–avibactam, since these agents were not available at the
time of study. It is conceivable that in vitro antimicrobial susceptibility rates to these agents may
be as high as combination regimens, particularly for P. aeruginosa [32,33]. However, the global use
of these new agents is concerning given the excessive cost and potential induction of antimicrobial
resistance once used in a large scale. Use of combination empirical therapy may provide additional
options to spare the use of these new agents and augment ongoing antimicrobial stewardship efforts.
In addition, the current study was focused on examination of in vitro antimicrobial susceptibility
testing of bloodstream isolates. Potential synergy of combination regimens and clinical outcomes were
not assessed. Future, preferably multicenter, clinical studies examining the effectiveness of empirical
combination antimicrobial therapy in patients with BSI due to P. aeruginosa in the setting of recent
beta-lactam use would yield highly valuable results. Finally, molecular and phylogenic testing was not
performed to identify specific resistance mechanisms of bloodstream isolates and determine E. coli
group, respectively.
4. Materials and Methods
4.1. Setting
The study was conducted at Palmetto Health Richland (multidisciplinary community teaching
hospital) and Palmetto Health Baptist (multidisciplinary community hospital) in Columbia, South
Carolina, USA. Both hospitals combine for over 1000 licensed beds. The Palmetto Health institutional
Review Board approved the study and waived informed consent.
4.2. Study Design and Definitions
Hospitalized adults with first episodes of monomicrobial BSI due to aerobic Gram-negative
bacilli from 1 January 2010 to 30 June 2015 at Palmetto Health Hospitals in Columbia, SC, USA
were identified through clinical decision support software and microbiology laboratory reports
(n = 1168). Receipt of prior antimicrobials was determined from medication administration records
and clinical notes from current or prior visits, electronic prescriptions in medical records from
prior visits to affiliated hospitals or ambulatory clinics, and third-party pharmacy adjudication
claims available in the electronic medical records. In vitro antimicrobial susceptibilities were
determined by the VITEK® 2 system using the Clinical and Laboratory Standards Institute (CLSI)
criteria. The antimicrobial drugs included on the susceptibility panel were amoxicillin/clavulanate,
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ampicillin, piperacillin/tazobactam, cefazolin, cefoxitin, ceftriaxone, ceftazidime, cefepime, ertapenem,
meropenem, gentamicin, tobramycin, ciprofloxacin, levofloxacin, and sulfamethoxazole/trimethoprim.
Screening for ESBL production by the disk diffusion method using cefotaxime/clavulanate combination
disks was performed in Enterobacteriaceae bloodstream isolates that were nonsusceptible in vitro to
any 3GC. Risk factors for 3GC resistance among patients with Enterobacteriaceae BSI included prior
beta-lactam or fluoroquinolone use within the past 3 months, prior infections or colonization with
ESBL-producing Enterobacteriaceae within the past 12 months, and recent outpatient gastrointestinal
or genitourinary procedures within the past one month as previously described [20]. Receipt of
beta-lactams within the past one month was considered a risk factor for 3GC resistance in patients with
BSI due to NFGN [21]. Antimicrobial susceptibilities to a 3GC, a fluoroquinolone (ciprofloxacin), and an
aminoglycoside (gentamicin) were recorded. The 3GC was defined as ceftriaxone for Enterobacteriaceae
and ceftazidime for NFGN. The bloodstream isolate was considered susceptible to a combination
regimen if it was in vitro susceptible to either or both agents in that combination.
4.3. Statistical Analysis
Matched pairs mean difference with 95% confidence intervals (CI) was calculated to examine
statistical significance of a change in antimicrobial susceptibility with the addition of a combination
agent (ciprofloxacin or gentamicin) to a 3GC in bloodstream isolates of Enterobacteriaceae and NFGN.
A stratified analysis was performed based on the presence of risk factors for 3GC resistance at initial
presentation. The utility of combination therapy for BSI due to Enterobacteriaceae and NFGN was
examined in patients with and without risk factors for 3GC resistance.
Kappa coefficients with 95% CI were calculated to assess correlation in susceptibilities between the
3GC and the respective combination agent (ciprofloxacin or gentamicin) for Enterobacteriaceae, NFGN
and subsets of bacteria from each group. For simplicity of statistical analysis, bloodstream isolates
were classified as either susceptible or nonsusceptible based on in vitro antimicrobial susceptibility
testing results using CLSI criteria.
The level of significance for statistical testing was defined as p < 0.05. JMP Pro (version 12.0; SAS
Institute, Cary, NC, USA) was used for all statistical analysis.
5. Conclusions
Empirical combination antimicrobial therapy had limited utility in Enterobacteriaceae BSI in this
patient population, even in the presence of risk factors for 3GC resistance. Conversely, combination
regimens provided significant additional in vitro antimicrobial coverage to ceftazidime in NFGN.
Patients with BSI due to P. aeruginosa and other NFGN, particularly those who used beta-lactams
within the past 30 days, benefited the most from combination therapy. Identification of patients with
BSI due to P. aeruginosa using clinical risk factors and/or rapid diagnostics and stratification by recent
beta-lactam use may be considered in the decision to use empirical combination therapy.
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